Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pinter

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2021
mTORC1 - a potential player in the pathogenesis of hidradenitis suppurativa?A Dmitriev, A König, V Lang, et al.
Journal of Virology|July 1, 1994
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibodyS V Warrier, A Pinter, W J Honnen, et al.
Journal of Virology|September 1, 1992
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoproteinM Thali, C Furman, D D Ho, et al.
The Journal of Dermatological Treatment|February 4, 2020
Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter studyC Kromer, D Wilsmann-Theis, S Gerdes, et al.
Journal of Virology|November 24, 2006
Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequenceW J Honnen, C Krachmarov, S C Kayman, et al.
Virology|October 30, 1979
Monoclonal antibodies against murine leukemia viruses: identification of six antigenic determinants on the p 15(E) and gp70 envelope proteinsM E Lostrom, M R Stone, M Tam, et al.
Journal of Virology|December 1, 1992
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved regionR Wyatt, M Thali, S Tilley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2023
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasisA Pinter, A Reich, P Arenberger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 17, 2020
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)A Pinter, M Hoffmann, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 31, 2023
A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasisB Halioua, G Caillet, C Taieb, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2021
mTORC1 - a potential player in the pathogenesis of hidradenitis suppurativa?A Dmitriev, A König, V Lang, et al.
Journal of Virology|July 1, 1994
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibodyS V Warrier, A Pinter, W J Honnen, et al.
Journal of Virology|September 1, 1992
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoproteinM Thali, C Furman, D D Ho, et al.
The Journal of Dermatological Treatment|February 4, 2020
Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter studyC Kromer, D Wilsmann-Theis, S Gerdes, et al.
Journal of Virology|November 24, 2006
Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequenceW J Honnen, C Krachmarov, S C Kayman, et al.
Virology|October 30, 1979
Monoclonal antibodies against murine leukemia viruses: identification of six antigenic determinants on the p 15(E) and gp70 envelope proteinsM E Lostrom, M R Stone, M Tam, et al.
Journal of Virology|December 1, 1992
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved regionR Wyatt, M Thali, S Tilley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2023
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasisA Pinter, A Reich, P Arenberger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 17, 2020
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)A Pinter, M Hoffmann, K Reich, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 31, 2023
A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasisB Halioua, G Caillet, C Taieb, et al.
Pageof 13